Balancing US/China Export Controls
Webinar | 06.21.22, 5:00 AM EDT - 6:00 AM EDT
Crowell & Moring attorneys will examine the myriad of challenges that companies face when balancing efforts to comply with the export regulations of both the United States and China. We will delve into both nations’ export control regulations and provide observations on areas to watch over the next year. Our areas of focus will include:
- U.S. Export Controls: China-focused restrictions such as what is subject to U.S. export controls, U.S. export restricted party lists, deemed export risks for Chinese nationals abroad, and U.S. reputational risks;
- Chinese Export Controls: An overview of China’s export control regime, the anti-foreign sanctions law, China’s blocking statute, and the unreliable entity list;
- Balancing the Two Regimes: Considerations for companies that are subject to both U.S. and Chinese export controls; and
- Areas to Watch Going Forward: Controls on emerging technology, semiconductors, and rare earth minerals, legislation in Congress, and “What If?” scenarios.
For more information, please visit these areas: Export Controls
Participants
Insights
Webinar | 12.10.26
The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations
The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.
Webinar | 11.17.26
Webinar | 11.13.26
Leveraging the Power of Connection to Better Support our Well-Being





